XPEL, Inc. XPEL
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -8.54%
- 1 year
- +31.82%
- Open
- 45.55
- Prev close
- 45.78
- Mkt cap
- 1.26B
- Vol
- 155.28K
- Avg vol
- 197.68K
- EPS
- 1.98
- P/E
- 23.06
- Div yield
- 0.00%
More statistics
- Low
- 45.34
- High
- 46.34
- Forward P/E
- 16.91
- Beta
- 1.18
- Short ratio
- 14.71
- Inst. own
- 86.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 46.20
- 200-d avg
- 46.25
- 1y target
- 61.67
Discussion (1)
Sign in to join the discussion
VICKY HANUKA XPEL 3 years ago #1$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.